In particular, the advent of anti-vascular endothelial growth factor (VEGF) drugs has transformed the treatment of retinal diseases such as neovascular age-related macular degeneration (AMD), diabetic macular oedema (DMO), and macular oedema secondary to retinal vein occlusions (RVO). Here, VEGFA is linked to wet macular degeneration.